Stevanato Group S P A (STVN) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Stevanato Group S p a   (NYSE: STVN)


Stevanato Group S P A 's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Stevanato Group S P A 's ROA in the fourth quarter of 2025?
Stevanato Group S p a achieved a return on average assets (ROA) of 5.5 % in its fourth quarter of 2025, which is below Stevanato Group S P A 's average return on assets, which stands at 6.55%.

ROA has improved compared to 4.73% in the third quarter of 2025, due to net income growth.

However, within the Healthcare sector 171 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 1277.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Total Assets Change 9.24 % 9.24 % 9.24 % 9.24 % 12.42 %
Y / Y Net Income Change 18.74 % - - - -19.17 %
Net Income (TTM) in million 157 132 132 132 132
Return On Assets (TTM) 5.5 % 4.73 % 4.83 % 4.94 % 5.06 %
STVN's Total Ranking # 1277 # # # # 1386
Total Assets (TTM) in million 2,849 2,849 2,849 2,849 2,608
Seq. Total Assets Change 0 % 0 % 0 % 9.24 % 0 %
Seq. Net Income Change - - - - -

STVN's 5 Years Annual ROA >> Back to STVN Management Effectiveness >> Compare STVN ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 50
Sector # 172
Overall # 1271

Return On Assets Statistics
High Average Low
8.62 %
6.55 %
5.06 %
(Dec 31 2022)   (Dec 31 2024)





Financial Statements
Stevanato Group S P A 's Assets $ 2,849 million STVN's Balance sheet
Stevanato Group S P A 's Income $ 157 million Quarterly STVN's Income Statement
STVN's Income by Division See STVN's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2019)
FY 2021
Y / Y Total Assets Change 9.24 % 12.42 % 24.82 % 57.02 % -
Total Assets in million 2,849 2,608 2,320 1,859 1,184
Y / Y Net Income Change 18.74 % -19.17 % 1.87 % 269.67 % -
Net Income in million 157 132 163 160 43
Annual Return On Assets 5.5 % 5.06 % 7.03 % 8.62 % 3.66 %

STVN's 5 Years Annual ROA >> Back to STVN Management Effectiveness >> Compare STVN ROA to its Competitors



Comment on STVN's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 5.5 % compared to prior year, due to annual net income growth of 18.74 % to $156.61 million, while value of Stevanato Group S P A 's overall assets grew just by 9.24 % to $2,849.25 million, compared to $2,849.25 a year before.


More Return On Assets Ratios
STVN's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
STVN's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for STVN's Competitors
Subscribers only: Roa for Stevanato Group S P A 's Suppliers
Subscribers only: Return On Assets for STVN's Customers

You may also want to know
STVN's Roi STVN's Inventory Turnover Ratio STVN's Growth Rates STVN's Dividend Comparisons
STVN's Profitability Ratios STVN's Asset Turnover Ratio STVN's Dividend Growth
STVN's Roe STVN's Valuation Ratios STVN's Financial Strength Ratios STVN's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Argenx Se  14.88 %
Gilead Sciences Inc   14.82 %
Merck and Co Inc   14.64 %
Intuitive Surgical Inc   14.53 %
Strata Critical Medical Inc   14.15 %
Halozyme Therapeutics Inc   14.09 %
Black Diamond Therapeutics Inc   13.91 %
Johnson and Johnson  13.76 %
Harmony Biosciences Holdings inc   13.67 %
Illumina Inc   13.55 %
Waters Corporation  13.35 %
Keros Therapeutics Inc   13.27 %
Prestige Consumer Healthcare Inc   13.25 %
Spero Therapeutics Inc   13.04 %
Hca Healthcare Inc   12.98 %
Novartis Ag  12.59 %
Embecta Corp   12.51 %
Sab Biotherapeutics Inc   12.51 %
Carlisle Companies Incorporated  12.51 %
Aveanna Healthcare Holdings Inc   12.41 %
West Pharmaceutical Services Inc   12.38 %
Inmode Ltd   12.24 %
Dexcom Inc   11.98 %
Corcept Therapeutics Inc  11.87 %
Neurocrine Biosciences Inc   11.62 %
Regeneron Pharmaceuticals Inc   11.51 %
Msa Safety Inc  11.28 %
Alpha Pro Tech Ltd   11.18 %
Lifevantage Corp  11.12 %
Encompass Health Corporation  11.09 %

Date modified: 2026-07-07T13:27:24+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.